Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial.
We conducted a single-blind, randomized trial of 2 dilutions (1:1 or 1:10) of Lancy-Vaxina vaccine (Berna Biotech) in vaccinia-naive persons (n=36) and persons previously vaccinated >25 years ago (n=76). All vaccinees responded successfully to the vaccination. There were no significant differences in the size of the skin lesions, the number of adverse events, the amount of viral shedding, or the level of antibody responses between the undiluted (n=56) and diluted (n = 56) vaccine groups. Compared with vaccinia-naive persons, previously vaccinated persons exhibited significantly smaller and more rapidly evolving skin lesions and fewer adverse events. Previously vaccinated persons had significantly higher neutralizing antibody levels before the administration of the study vaccine than vaccinia-naive persons, and viral shedding from lesions in previously vaccinated persons was lower and diminished more rapidly than from lesions in vaccinia-naive persons.
Kim
Sung-Han
SH
Department of Virology, National Institute of Health, Seoul, South Korea.
Yeo
Sang-Gu
SG
Jang
Hee-Chang
HC
Park
Wan-Beom
WB
Lee
Chang-Seop
CS
Lee
Ki-Deok
KD
Kim
Hong-Bin
HB
Kim
Nam-Joong
NJ
Kim
Young-Taek
YT
Jee
Youngmee
Y
Cho
Haewol
H
Oh
Myoung-don
MD
Choe
Kang-Won
KW
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D009500:Neutralization Tests; D016037:Single-Blind Method; D012867:Skin / Q000473:pathology; D012900:Smallpox Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D014616:Vaccinia virus / Q000276:immunology / Q000302:isolation & purification; D017201:Virus Shedding
D000914:Antibodies, Viral; D012900:Smallpox Vaccine